Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax and Evaluation of the co-Administration With Fluarix of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age.

Trial Profile

Lot-to-Lot Consistency, Non-Inferiority Versus Mencevax and Evaluation of the co-Administration With Fluarix of GSK Biologicals' Meningococcal Vaccine GSK134612, in Healthy Subjects Aged 18 Through 55 Years of Age.

Completed
Phase of Trial: Phase III

Latest Information Update: 19 Dec 2016

At a glance

  • Drugs Influenza virus vaccine (Primary) ; Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Influenza virus infections; Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics; Registrational
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 21 May 2012 Actual end date changed from Nov 2007 to May 2008 as reported by ClinicalTrials.gov.
    • 07 Sep 2008 Primary end point added as reported by ClinicalTrials.gov.
    • 07 Sep 2008 Additional drug identified Fluarix as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top